Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iloprost inhalation - Pharmosa Biopharm

Next Previous
Drug Profile

Iloprost inhalation - Pharmosa Biopharm

Alternative Names: L608; Liposomal iloprost controlled release - Pharmosa BioPharm; Liposomal Iloprost sustained release - Pharmosa BioPharm

Latest Information Update: 23 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmosa Biopharm
  • Class Alkynes; Anti-ischaemics; Antiplatelets; Peripheral vasodilators; Prostaglandins; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Epoprostenol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pulmonary arterial hypertension
  • Preclinical Raynaud's disease

Most Recent Events

  • 24 Oct 2025 Pharmacokinetics data from phase I trial in Pulmonary arterial hypertension presented at the ACR Convergence 2025 (ACR/ARP-2025)
  • 27 Sep 2025 Pharmacokinetics and adverse event data from phase I trial in Pulmonary arterial hypertension presented at the 35th Annual Congress of the European Respiratory Society (ERS-2025)
  • 11 Apr 2025 Phase-I clinical trials in Pulmonary arterial hypertension (In volunteers) in New Zealand (Inhalation) (NCT06429930)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top